Ocean Biomedical Inc (OCEA)
Ocean Biomedical Inc is a biopharmaceutical company listed on OTC Markets under the common stock symbol OCEA. The company focuses on discovering and developing therapeutic candidates in oncology, fibrosis, and infectious diseases. Its oncology pipeline includes programs such as OCX-253, OCX-410, and OCX-909, which are being studied for cancers including non-small cell lung cancer and glioblastoma multiforme. In fibrosis, its candidates include OCF-203 for idiopathic pulmonary fibrosis and Hermansky-Pudlak syndrome. The infectious disease portfolio includes malaria-related programs such as ODA-570, ODA-611, and ODA-579. Ocean Biomedical also has a license agreement with Elkurt, Inc. covering several antibody, bispecific, antifibrotic, and malaria-related assets. Founded in 2019 and based in Providence, Rhode Island, the company is a subsidiary of Poseidon Bio, LLC.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-OCEA
|
—
|
—
|
—
|
—
|
—
|
—
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 14, 2026
|
—
|
—
|
—
|
92.946 K
|
—
|
—
|
—
|
—
|
—
|
—
|